Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protagonist Therapeutics (PTGX) EPS (Basic) (2017 - 2025)

Protagonist Therapeutics (PTGX) has disclosed EPS (Basic) for 9 consecutive years, with -$0.7 as the latest value for Q4 2025.

  • Quarterly EPS (Basic) fell 132.86% to -$0.7 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.06 through Dec 2025, down 145.78% year-over-year, with the annual reading at -$2.05 for FY2025, 145.86% down from the prior year.
  • EPS (Basic) hit -$0.7 in Q4 2025 for Protagonist Therapeutics, down from -$0.62 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $3.41 in Q1 2024 to a low of -$0.84 in Q2 2022.
  • Historically, EPS (Basic) has averaged -$0.21 across 5 years, with a median of -$0.6 in 2023.
  • Biggest five-year swings in EPS (Basic): plummeted 233.33% in 2021 and later surged 608.96% in 2024.
  • Year by year, EPS (Basic) stood at -$0.77 in 2021, then increased by 9.09% to -$0.7 in 2022, then surged by 174.29% to $0.52 in 2023, then skyrocketed by 309.62% to $2.13 in 2024, then plummeted by 132.86% to -$0.7 in 2025.
  • Business Quant data shows EPS (Basic) for PTGX at -$0.7 in Q4 2025, -$0.62 in Q3 2025, and -$0.55 in Q2 2025.